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Abstract: The new anti-aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6. Ritonavir is a
potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor. The aim of this open-label cross-over study was to
assess the effect of ritonavir on prasugrel active metabolite (prasugrel AM) pharmacokinetics in healthy volunteers. Ten healthy
male volunteers received 10 mg prasugrel. After at least a week washout, they received 100 mg ritonavir, followed by 10 mg
prasugrel 2 hr later. We used dried blood spot sampling method to monitor prasugrel AM pharmacokinetics (Cmax, t1/2, tmax,
AUC0–6 hr) at 0, 0.25, 0.5, 1, 1.5, 2, 4 and 6 hr after prasugrel administration. A ‘cocktail’ approach was used to measure
CYP2B6, 2C9, 2C19 and 3A activities. In the presence of ritonavir, prasugrel AM Cmax and AUC were decreased by 45% (mean
ratio: 0.55, CI 90%: 0.40–0.7, p = 0.007) and 38% (mean ratio: 0.62, CI 90%: 0.54–0.7, p = 0.005), respectively, while t1/2 and
tmax were not affected. Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus
0.13 ± 0.07) reﬂecting an almost complete inhibition of CYP3A4, whereas omeprazole, ﬂurbiprofen and bupropion MR were not
affected. These data demonstrate that ritonavir is able to block prasugrel CYP3A4 bioactivation. This CYP-mediated drug–drug
interaction might lead to a signiﬁcant reduction of prasugrel efﬁcacy in HIV-infected patients with acute coronary syndrome.
Introduction
Prasugrel is a recently commercialized thienopyridine antiplat-
elet agent used to prevent atherothrombotic events in patients
with acute coronary syndrome who are undergoing percutane-
ous coronary intervention [1].
The active metabolite of prasugrel (prasugrel AM) is an irre-
versible inhibitor of ADP-P2Y12 platelet receptors, explaining
the anti-aggregating effect of prasugrel. This pro-drug is rap-
idly hydrolysed by carboxylesterases into a thiolactone inter-
mediate metabolite that is transformed by cytochromes P450
(CYP) into its pharmacologically active metabolite (ﬁg. 1).
CYP3A and CYP2B6 are primarily responsible for this trans-
formation while CYP2C19 and CYP2C9 are involved to a les-
ser extent [2]. CYP3A and 2B6 represent, respectively, 40%
and 5% of the total cytochromes in the human liver and they
are known to be involved in the oxidative metabolism of a
wide range of drugs in clinical use [3,4]. Consequently, in vivo
interactions between prasugrel and other drugs affecting these
CYPs are possible. The effects of some CYP inhibitors or in-
ducers on prasugrel bioactivation have been assessed previ-
ously. For example, there was no change in prasugrel AM
formation or the inhibition of platelet aggregation when prasu-
grel was administered with ketoconazole (a CYP3A inhibitor),
atorvastatin (a CYP3A substrate) or rifampicin (a CYP3A
inducer) [5–7]. These studies suggest that the production of
prasugrel AM is not altered by induction or inhibition of
CYP3A. However, an in vitro study showed that prasugrel
was mainly metabolized by CYP3A and CYP2B6 and simulta-
neous inhibition of these two pathways signiﬁcantly decreased
prasugrel bioactivation. Indeed, ritonavir was a potent inhibitor
of prasugrel bioactivation in human liver microsomes, raising
the possibility of a pharmacokinetic drug–drug interaction
between ritonavir and prasugrel in vivo [8]. Such an interaction
could reduce the efﬁcacy of prasugrel. In vivo experiments are
lacking to conﬁrm these in vitro data in human beings.
Ritonavir is an antiretroviral agent widely used as a pharma-
cokinetic booster in patients with HIV infection to increase
the plasma concentrations of other antiretroviral drugs. In HIV
patients with acute coronary syndrome, these two drugs could
be largely prescribed concomitantly. Indeed, ritonavir is
known to be a potent inhibitor of CYP3A and CYP2B6 and is
a weaker inhibitor of CYP2C9 [8–12].
While blood volume is seldom a major limitation of clinical
trials, the invasiveness of phlebotomy certainly is. Compared
with classic venipuncture, dried blood spots (DBS) sampling
is less invasive and can be easily performed. Additionally,
when shipping and storing samples, DBS sampling eliminates
the need for dry ice, plasma separation and addition of antico-
agulants that are required to maintain the viability of tradi-
tional blood samples. Regarding these beneﬁts, DBS sampling
has grown in popularity in the clinical and the pharmaceutical
communities over the past decade. Recent publications demon-
strated that DBS is a viable approach for the quantitative
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measurement of drugs and metabolites both in human beings
and animals [13–15].
In our study, we assessed the potential pharmacokinetic
interaction between ritonavir and prasugrel in healthy volun-
teers. The activities of the CYPs involved in prasugrel metab-
olism were also evaluated using a cocktail approach.
Material and Methods
Volunteers. Inclusion criteria required that volunteers be healthy
males between 18 and 60 years of age, have a body mass index
between 18 and 25 kg/m2, and be able to understand and read the
French language. Candidates were ineligible if they were smokers;
were hypersensitive to prasugrel, ritonavir or constituents of the
tablets; consumed alcohol regularly; had concomitant disease; or used
any drug or food such as grapefruit in the month prior to the study
that can either affect or be metabolized by CYP3A, 2C19, 2B6 and
2C9. Volunteers who used drugs associated with an increased risk of
bleeding in the 10 days preceding the start of the study were excluded,
as were those with a familial history of clotting disorders, antecedent
of haemorrhagic disease, a previous or active gastrointestinal ulcer.
Study design. This open-label cross-over study was conducted in 10
healthy volunteers at the clinical research unit of the Geneva
University Hospitals. This study was conducted in accordance with
Good Clinical Practice Guidelines and the Declaration of Helsinki.
The Geneva University Hospital Ethics Committee and the
Institutional Review Board Swissmedic approved the protocol before
the study began. This clinical trial was registered at http://www.
clinicaltrials.gov (NCT01346800). Written informed consent was
obtained from each participant before the study. Volunteers received a
single oral dose of 10 mg prasugrel on the ﬁrst day. After at least one
week, they received 100 mg ritonavir followed by 10 mg prasugrel
2 hr later. At each session, they also received a ‘micrococktail’
containing 10 mg bupropion, 5 mg ﬂurbiprofen, 2 mg omeprazole and
0.1 mg midazolam for phenotyping of CYP2B6, CYP2C9, CYP2C19
and CYP3A, respectively, 1.5 hr after micrococktail administration.
Adverse events were assessed during the study.
Each individual participated in the study for approximately 3 weeks,
from initial screening to the ﬁnal session.
Analysis of DBS samples. Capillary blood samples for
pharmacokinetic analysis were collected prior to and 0.25, 0.5, 1, 1.5,
2, 3, 4 and 6 hr after the administration of a single dose of prasugrel.
After a small ﬁnger prick using disposable lancet (BD Microtainer:
Contact-Activated Lancet, United Kingdom), 5 ll blood was spotted
onto ﬁlter paper (Protein Saver 903 Card, Whatman) that had been
previously soaked with 20 ll of 2-bromo-3’-methoxyacetophenone
(BMAP) at 30 mM. This pre-treatment allows the unstable thiol group
in prasugrel AM to form a disulphide bond with BMAP. Samples
were stored at 20°C until analysis.
The DBS concentrations of prasugrel AM midazolam, omeprazole,
bupropion and ﬂurbiprofen were measured on a LC-MS/MS platform
consisting of a 5500 QTtrap® triple quadrupole linear ion trap mass
spectrometer equipped with a TurboIon SprayTM interface (AB Sciex,
Darmstadt, Germany) and an Ultimate 3000 RS pump (Dionex) as the
LC system. Data were acquired and processed using Analyst software
(version 1.5.1; AB Sciex).
Analytical method description. Before analysis, discs (i.d. 6 mm)
covering the entire DBS were punched out and placed in the bottom of
individual LC vials containing a 300 lL inert insert (BGB Analytik,
Germany). Samples were extracted by adding 100 lL of methanol
containing 1 ng/ml derivatized prasugrel AM-d3 (Sirius Fine Chemicals,
Germany). After 30 min., 5 lL of the supernatant was injected into the
LC-MS/MS system.
The analytes were separated on a Kinetex Phenomenex (Brechbüh-
ler, Switzerland) RP C18 column (50 9 2.1 mm, 2.6 lm particles i.
d.) using a gradient elution mode running from water–acetonitrile
98:2, v/v to water–acetonitrile 10:90, v/v for 2 min. The total run time
was 6 min., including column wash and equilibration. After electro-
spray ionization (ESI), MS/MS detection was carried out with multiple
reactions monitoring (MRM) at unit resolution operating in dual mode
(positive and negative) with a time settling of 65 ms.
The instrument parameters were manually optimized as follows:
curtain gas: 20 psi; ion source gas 1 and 2 (GS1 and GS2): 30 and
40 psi, respectively; ion source voltage: 5000 V in positive ESI mode
and 4500 V in negative ESI mode; temperature: 650°C; entrance
potential and collision cell exit potential: 10 V in positive ESI mode
and 10 V in negative mode. The MRM transitions of the analytes
relevant to this study are summarized in table 1.
Validation. The method was fully validated according to the
guidelines of the European Medicines Agency on validation of
bioanalytical methods based on three non-consecutive days of testing
[16]. A typical validation day consisted of 5 DBS calibrators (Cal)
injected in duplicate (n = 2) and 4 DBS quality controls (QC) injected
in quadruplicate (n = 4). Cal and QC DBS samples were prepared
independently in the same way using fresh human EDTA blood
Fig. 1. Metabolic pathways of the anti-aggregating agent prasugrel [8].
© 2012 The Authors
Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society
EFFECT OF RITONAVIR ON PRASUGREL PHARMACOKINETICS 133
(supplied by the University Hospitals of Geneva). The calibration
curves were linear over the standard concentration ranges of 0.1–
50 ng/ml for midazolam; 0.5–250 ng/ml for prasugrel AM,
omeprazole and bupropion; and 50–10,000 ng/ml for ﬂurbiprofen.
Based on these calibration curves, the trueness expressed as relative
bias and the intermediate precision of the QCs was calculated. The
values were within the expected criteria (±15%) for all the analytes.
The selectivity of the method was investigated by injecting DBS pre-
treated with BMAP obtained from the 10 volunteers recruited in the
study. No interfering peaks were observed in the retention window of
the analytes nor were there any matrix effects (<15%).
To ensure that the DBS specimens collected during the study could
be shipped and stored at ambient temperature for a short period, the ana-
lytes’ stability was investigated over 30 days at three different tempera-
tures (i.e. 20°C, +4°C and room temperature). The assay showed that
all compounds were stable at the tested temperatures, as back-calculated
concentrations were comprised between 85% and 115% of the corre-
sponding 1-day-old DBS samples. As no signiﬁcant difference was
observed between storage at room temperature and at 20°C, DBS
cards could be collected, shipped and stored at ambient temperature.
Moreover, reinjection of study DBS samples that were stored at 20°C
for 6 months showed similar results to those previously obtained.
Phenotyping in plasma samples. A blood sample (approximately
6 ml) was obtained 1.5 hr after administration of the ‘micrococktail’
at each session for phenotyping. Blood samples were immediately
centrifuged and the separated plasma was stored at 20°C until
analysis. We used the validated extraction methods routinely used in
our laboratory. Omeprazole, ﬂurbiprofen, midazolam and their
metabolites were extracted as described previously [17]. Bupropion
was extracted by a liquid–liquid extraction procedure. All probes and
their metabolites were analysed by the LC–MS/MS method described
in the previous section.
Size calculation. To detect an inhibition of prasugrel AM formation
by ritonavir of at least 20 ± 10% with a power of 80% and a = 0.05,
eight volunteers were needed. Two additional volunteers were
recruited in case of volunteer withdrawal.
Statistics. The pharmacokinetic parameters of prasugrel AM,
midazolam, bupropion, ﬂurbiprofen and omeprazole were calculated
using a non-compartmental method by WinNonLin® version 5.2
(Pharsight, Mountain View, CA, USA). All statistical tests were
performed with SPSS version 17 (Chicago, IL, USA). According
to regulatory guidelines, results were presented as the mean values
(±S.D.) or as mean ratios with 90% conﬁdence intervals. The values
for tmax were presented as median (range). The effect of ritonavir on
the pharmacokinetic variables of prasugrel was estimated with the
Wilcoxon signed rank test using SPSS version 17. All statistical tests
were interpreted at the 5% signiﬁcance level (two-sided).
Results
Volunteers.
Ten healthy male volunteers were enrolled in the study. Vol-
unteers were between 21 and 41 years of age with a mean
(±S.D.) of 26 ± 6 years. Volunteers ranged in height from
165 to 185 cm, weighed between 63 and 95 kg and had a
mean body mass index (±S.D.) of 22.8 ± 2 kg/m2. They were
in good health, as determined by review of their medical his-
tory and physical examination. All 10 volunteers successfully
completed the study. No adverse effects were reported during
the study and all volunteers were included in the pharmacoki-
netic analysis. One volunteer was excluded from the evalua-
tion of CYP2C19 activity because omeprazole and its
metabolite were not detectable in his plasma and DBS.
Prasugrel pharmacokinetics.
In comparison with prasugrel alone, AUC0–6 hr and Cmax
decreased by 38.4% (mean ratio: 0.62, CI 90%: 0.54; 0.7,
p = 0.005) and 44.9% (mean ratio: 0.55, CI 90%: 0.4; 0.7,
p = 0.007), respectively, when ritonavir was administered with
prasugrel. However, ritonavir did not affect the time to reach
maximum concentration (tmax; median ratio: 1, CI 90%: 0.5;
2, p = 0.73) and half-life (t1/2; mean ratio: 0.94, CI 90%:
0.66; 1.22, p = 0.33) of prasugrel AM (ﬁgs 2 and 3; table 2).
Cytochrome P450 activities.
Midazolam MR was 97.8 ± 1.4% lower after ritonavir administra-
tion compared with the values for prasugrel alone (mean ratio:
0.022, CI 90%: 0.014; 0.03, p = 0.005). When ritonavir was co-
administered with prasugrel, midazolam AUC0–6 hr and Cmax were
26 times and 6 times, respectively, the values obtained for prasugrel
alone. Omeprazole MR (mean ratio: 0.92, CI 90%: 0.49; 1.35,
p = 0.59), AUC0–6 hr (mean ratio: 1.25, CI 90%: 0.94; 1.57,
p = 0.44) and Cmax (mean ratio: 1.54, CI 90%: 0.77; 2.32, p = 0.44)
were not affected by ritonavir, and neither were ﬂurbiprofen
MR (mean ratio: 1.02, CI 90%: 0.78; 1.26, p = 0.58),
AUC0–6 hr (mean ratio: 0.95, CI 90%: 0.84; 1.05, p = 0.44) or Cmax
(mean ratio: 0.98, CI 90%: 0.82; 1.14, p = 0.72). Unexpectedly,
Table 1.
Multiple reactions monitoring parameters for the detection of prasugrel, prasugrel active metabolite, prasugrel active metabolite-d3, midazolam,
omeprazole, bupropion and ﬂurbiprofen.
Compounds Polarity Q1?Q3 (m/z) CE (V) DP (V) Dwell time (ms) LLQ (ng/ml)
Prasugrel + 374?206 23 100 2 0.5
Prasugrel AM1 + 498?348 28 100 2 0.5
Prasugrel AM-d3
1 + 501?348 25 150 2 0.5
Midazolam + 326?291 37 165 2 0.1
Omeprazole + 346?198 19 66 2 0.5
Bupropion + 240?131 30 80 2 0.5
Flurbiprofen + 243?199 18 50 2 100
CE, collision energy; DP, declustering potential; LLQ, lower limit of quantiﬁcation.
1Compounds derivatized with 2-bromo-3-methoxyacetophenone (BMAP).
© 2012 The Authors
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bupropion MR (mean ratio: 1.02, CI 90%: 0.85; 1.19, p = 0.88),
AUC0–6 hr (mean ratio: 1, CI 90%: 0.93; 1.1, p = 0.96) and Cmax
(mean ratio: 1.03, CI 90%: 0.85; 1.21, p = 0.96) were not inﬂuenced
by the co-administration of ritonavir and prasugrel (table 3; ﬁg. 4).
Discussion
This study shows that prasugrel pharmacokinetics is signiﬁ-
cantly altered by ritonavir. In fact, ritonavir signiﬁcantly
decreased prasugrel AM AUC0–6 hr and Cmax while tmax and
t1/2 were not affected.
As determined from a previous in vitro study, 38–70% of
the bioactivation of oxo-prasugrel to prasugrel AM is per-
formed by CYP3A4 and 2–26% is performed by CYP2B6 [2].
In the present study, ritonavir was used to investigate the
effect of the inhibition of CYP3A and possibly other CYPs on
the prasugrel AM pharmacokinetics.
In the present study, ritonavir totally inhibited CYP3A4/5
activity as indicated by the decrease of more than 97% of mi-
dazolam MR and the increase of midazolam’s AUC0–6 hr to a
level 26 times that of observed without ritonavir, and the
increase of midazolam’s Cmax to a level 6 times that observed
without ritonavir. These results are in agreement with previous
studies demonstrating that ritonavir is a very potent CYP3A
inhibitor [11,18]. A previous study assessing the effect of ke-
toconazole on prasugrel pharmacokinetics and pharmacody-
namics demonstrated a decrease in prasugrel AM Cmax while
AUC and platelet aggregation were not affected [5]. These
contradictory results might be due to a higher CYP3A inhibi-
tion potential of ritonavir in comparison with ketoconazole
[19]. In fact, ritonavir inhibited CYP3A more strongly than
ketoconazole, as indicated by its increase of midazolam’s
AUC by a factor 28.4 while ketoconazole increased it by a
factor 10–15 [18,20,21]. The pharmacokinetic differences
between the results of ketoconazole and ritonavir could be
explained by the mechanism of inhibition of the CYP3A4 by
these molecules: while ritonavir is a competitive and non-com-
petitive irreversible inhibitor, ketoconazole is only a competi-
tive reversible inhibitor of CYP3A4.
Regarding CYP2B6 activity, ritonavir did not signiﬁcantly
affect either bupropion or 5-hydroxybupropion pharmacokinet-
ics. This may be explained by the high Ki (5 lM) value of
CYP2B6, which is higher than the expected ritonavir Cmax after
a 100 mg dose (1–2 lM) [22]. Higher concentrations of ritona-
vir might therefore be necessary to highlight any CYP2B6 inhi-
bition measured through bupropion metabolism. Furthermore,
omeprazole MR, ﬂurbiprofen MR and their pharmacokinetic
parameters did not change after ritonavir treatment.
One limitation of this study was that ritonavir was adminis-
tered as a single dose. Ritonavir is one of the most potent
known inhibitors of CYP3A but may have an induction effect
when administered long-term [23]. However, this remains con-
troversial, because some in vivo studies have failed to demon-
strate induction and instead reported persistent CYP3A
inhibition, even after long-term use [24]. The data obtained in
our study are consistent with a pharmacokinetic drug–drug
interaction between prasugrel and ritonavir via a potent inhibi-
tion of CYP3A4/5. Pharmacodynamic measurements were not
performed in this study as prasugrel was administered in sin-
gle dose. Nevertheless, according to some studies, from a clin-
ical point of view, decreases in prasugrel AM production may
be associated with lower platelet inhibition [25,26].
In conclusion, the inhibition of the bioactivation pathways
of prasugrel by ritonavir mainly via CYP3A4/5 signiﬁcantly
affected prasugrel AM pharmacokinetics. This study highlights
the importance of very carefully considering drugs affecting
CYPs that might be prescribed concomitantly with prasugrel.
Prasugrel is metabolized mainly by the CYP3A isoform that is
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Fig. 2. Mean (±S.D.) whole blood concentrations for prasugrel’s
active metabolite in dried blood spots after prasugrel alone (D) or
prasugrel with ritonavir (●). Values are shown as the mean ± S.D.
A
B
Fig. 3. Effect of ritonavir on individual (A) AUC0–6 hr or (B) Cmax of
the prasugrel active metabolite after administration of 10 mg prasugrel
alone or 10 mg prasugrel with 100 mg ritonavir. *p < 0.05,
**p  0.005.
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Fig. 4. Effect of ritonavir on individual metabolic ratios of (A) midazolam, (B) ﬂurbiprofen, (C) omeprazole and (D) bupropion after administration
of 10 mg prasugrel or 10 mg prasugrel with 100 mg ritonavir. *p < 0.05, **p  0.005.
Table 3.
Pharmacokinetic parameters estimated from dried blood spots analysis and metabolic ratios of midazolam, bupropion, omeprazole and ﬂurbiprofen
measured in plasma.
Prasugrel alone Prasugrel + ritonavir Ratio CI 90% p-value
Midazolam
Cmax 0.17 (0.09) 0.75 (0.29) 6.1 (3.5; 8.7) 0.005
AUC 0.31 (0.26) 2.53 (1.12) 26.5 (1.8; 51.3) 0.005
Metabolic Ratio (OH midazolam/midazolam) 6.74 (2.64) 0.13 (0.07) 0.022 (0.014; 0.03) 0.005
Bupropion
Cmax 20.9 (6.3) 21.5 (8.2) 1.03 (0.85; 1.21) 0.96
AUC 49.1 (14.1) 49.3 (16.1) 1 (0.93; 1.1) 0.96
Metabolic Ratio (OH bupropion/bupropion) 1.70 (0.59) 1.72 (0.73) 1.02 (0.85; 1.19) 0.88
Omeprazole
Cmax 35.6 (32.1) 37.3 (32.5) 1.54 (0.77; 2.32) 0.44
AUC 81.9 (96.5) 96.5 (111.9) 1.25 (0.94; 1.57) 0.44
Metabolic Ratio (OH omeprazole/omeprazole) 0.92 (1.13) 1.1 (1.25) 0.92 (0.49; 1.35) 0.59
Flurbiprofen
Cmax 1135.7 (684.4) 1095 (653.8) 0.98 (0.82; 1.14) 0.72
AUC 3872.7 (2178.1) 3679.4 (2132.8) 0.95 (0.84; 1.05) 0.44
Metabolic Ratio (OH ﬂurbiprofen/ﬂurbiprofen) 0.037 (0.01) 0.034 (0.008) 1.02 (0.78; 1.26) 0.58
Values are presented as the means (±S.D.) or mean ratios (prasugrel + ritonavir versus prasugrel alone) with 90% conﬁdence intervals (CI 90%).
Cmax, maximal concentration; AUC, area under the concentration-time curve; Signiﬁcant values (p < 0.05) were highlighted in bold.
Table 2.
Pharmacokinetic parameters of prasugrel active metabolite.
Prasugrel alone Prasugrel + ritonavir
Ratio (prasugrel + ritonavir versus
prasugrel alone) CI 90% p-value
tmax, hr 0.5 (0.5–1) 0.5 (0.25–1.5) 1 0.5–2 0.73
t1/2, hr 1.62 (0.54) 1.42 (0.66) 0.94 0.66–1.22 0.33
Cmax, ng/ml 389.8 (226.2) 185.4 (83.1) 0.55 0.40–0.7 0.007
AUC, hr ng/ml 339.6 (144.7) 207.5 (91.1) 0.62 0.54–0.7 0.005
Values are presented as the means (±S.D.) for t1/2, Cmax and AUC and as median (range) for tmax values or mean ratios (prasugrel + ritonavir
versus prasugrel alone) with 90% conﬁdence intervals (CI 90%).
tmax, time to reach maximal concentration; t1/2, elimination half-life; Cmax, maximal concentration; AUC, area under the concentration-time curve;
Signiﬁcant values (p< 0.05) were highlighted in bold.
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inhibited, for example, by imatinib, ketoconazole and other
antiretroviral drugs. CYP2B6, which is involved in the metab-
olism of prasugrel, also metabolizes other drugs such as
methadone, cyclophosphamides and tramadol. Further PK/PD
studies are needed to investigate the impact of these
CYP-mediated drug–drug interactions on patients receiving
prasugrel treatment and particularly in HIV patients with acute
coronary syndrome simultaneously treated by prasugrel and
ritonavir.
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